Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 1851 • 2019 ACR/ARP Annual Meeting
The Association of Discrimination and Stress on Cardiovascular Disease in a Population-Based Cohort with Systemic Lupus Erythematosus
S Sam Lim¹, Gaobin Bao ¹, Charles Helmick ², Charmayne Dunlop-Thomas ³ and Cristina Drenkard ¹, ¹Emory University, Atlanta, GA, ²Centers for Disease Control and Prevention, Division of Population Health, Atlanta, GA, ³Emory University, Atlanta, Georgia
Background/Purpose: African Americans (AA) are more likely to experience psychosocial and environmental stressors and develop SLE than whites. Increasing frequency of racial discrimination is associated…
Abstract Number: 2043 • 2019 ACR/ARP Annual Meeting
Large Joint Arthritis in Systemic Lupus Erythematosus Is Characterized by TH17 Cells Rather Than B Cell Accumulation
Natalie Sippl¹, Francesca Faustini ¹, Karine Chemin ¹, Iva Gunnarsson ² and Vivianne Malmström ³, ¹Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden, ²Division of Rheumatology, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, ³Rheumatology Unit, Department of Medicine, Karolinska University Hospital and Institutet, Stockholm, Sweden., Stockholm, Sweden
Background/Purpose: Arthritis is a common clinical feature of systemic lupus erythematosus (SLE), that can be present either at the onset or in later disease course.…
Abstract Number: 2523 • 2019 ACR/ARP Annual Meeting
Contemporary Prescription Opioid Use and Predictors Among Patients with Systemic Lupus Erythematosus
April Jorge¹, Na Lu ² and Hyon K. Choi ¹, ¹Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hosptial, Boston, MA
Background/Purpose: SLE is a complex illness that can be associated with chronic pain. In recent years, an international opioid epidemic has become a major public…
Abstract Number: 2559 • 2019 ACR/ARP Annual Meeting
A Phase 2, Open-label Extension Study to Evaluate Long-term Safety of Anifrolumab in Adults with Systemic Lupus Erythematosus
W. Winn Chatham ¹, Richard Furie ², Amit Saxena ³, Philip Brohawn ⁴, Erik Schwetje⁵, Gabriel Abreu ⁶ and Raj Tummala ⁵, ¹University of Alabama Medical Center, Birmingham, AL, ²Zucker School of Medicine at Hofstra/Northwell, New York, NY, ³NYU Langone Orthopedic Center, New York, ⁴AstraZeneca, Gaithersburg, MD, ⁵AstraZeneca, Gaithersburg, MD, USA, Gaithersburg, MD, ⁶AstraZeneca, Gothenburg, Sweden, Gothenburg, Sweden
Background/Purpose: Anifrolumab is a fully human, IgG1κ monoclonal antibody that binds to the type I IFN receptor and inhibits activity of all type I IFNs.1…
Abstract Number: 2792 • 2019 ACR/ARP Annual Meeting
The Need for Personalized, Non-Pharmacological Intervention Programmes in Autoimmune Connective Tissue Disorders: Results of a EULAR-Funded Scoping Review with a Nested, Descriptive Meta-Analysis
Valentin Ritschl¹, Ricardo Ferreira ², Rúben Fernandes ², Eduardo Santos ², Essi Juutila ³, Erika Mosor ¹, Kim Fligelstone ⁴, Helena Gaspar ⁵, Linda Schraven ⁶, Judy Ammerlaan ⁷, Georg Stummvoll ⁸, Maria João Salvador ², Janet Poole ⁹, Cornelia van den Ende ¹⁰, Carina Boström ¹¹ and Tanja Stamm ¹, ¹Medical University of Vienna, Vienna, Austria, ²Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal, ³Metropolia University of Applied Sciences, Helsinki, Finland, ⁴Federation of European Scleroderma Associations, Tournai, Belgium, ⁵Portuguese League Against Rheumatic Diseases, Portugal, Portugal, ⁶Federation of European Scleroderma Associations, Sweden, Sweden, ⁷University Medical Centre, Utrecht, Netherlands, ⁸Klinikum Malcherhof Baden, Baden, Austria, ⁹University of New Mexico, Albuquerque, NM, ¹⁰Sint Maartenskliniek Nijmegen, Nijmegen, Netherlands, ¹¹Karolinska Institutet, Stockholm, Sweden
Background/Purpose: Autoimmune Connective Tissue Disorders (CTDs), including Mixed Connective Tissue Disorders (MCTD), systemic sclerosis (SSc) and systemic lupus erythematous (SLE) can lead to Raynaud phenomenon,…
Abstract Number: 101 • 2018 ACR/ARHP Annual Meeting
Regulation of Monocyte Function By Epstein Barr Virus Interleukin-10 (vIL10) in Systemic Lupus Erythematosus
Neelakshi R. Jog¹, Eliza Chakravarty¹, Joel M. Guthridge¹ and Judith A. James^2,3, ¹Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Arthritis & Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Department of Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, OK
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a systemic autoimmune disease characterized by periods of elevated and suppressed disease activity. Epstein Barr Virus (EBV) has been…
Abstract Number: 738 • 2018 ACR/ARHP Annual Meeting
Two Clinical Phenotypes of Chinese SLE-PAH Patients
Fangfang Sun¹, Wanlong Wu², Li Guo¹, Zhiwei Chen¹, Xiaodong Wang¹, Ting Li¹ and Shuang Ye¹, ¹Rheumatology, Ren Ji Hospital, South Campus, School of Medicine, Shanghai Jiaotong University, Shanghai, China, ²Department of Rheumatology, South Campus, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China
Background/Purpose: Pulmonary arterial hypertension (PAH) is a severe complication of systemic lupus erythematosus (SLE), which is the most common underlying disease of CTD associated PAH.…
Abstract Number: 970 • 2018 ACR/ARHP Annual Meeting
Baricitinib in Patients with Systemic Lupus Erythematosus: Results from a Phase 2, Randomized, Double-Blind, Placebo-Controlled Study
Daniel J. Wallace¹, Richard Furie², Yoshiya Tanaka³, Kenneth C. Kalunian⁴, Marta Mosca⁵, Michelle Petri⁶, Thomas Dorner⁷, Mario H. Cardiel⁸, Ian N. Bruce⁹, Elisa Gomez¹⁰, Amy M. DeLozier¹⁰, Jonathan Janes¹⁰, Matthew D Linnik¹⁰, Stephanie de Bono¹⁰, Maria E. Silk¹⁰ and Robert W. Hoffman¹⁰, ¹Cedars-Sinai Medical Center/David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA, ²Division of Rheumatology, Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY, ³University of Occupational and Environmental Health, Kitakyushu, Japan, ⁴University of California at San Diego School of Medicine, La Jolla, CA, ⁵University of Pisa, Pisa, Italy, ⁶Medicine (Rheumatology), Johns Hopkins University School of Medicine, Baltimore, MD, ⁷Charité Universitätmedizin Berlin and Deutsches Rheumaforschungszentrum (DRFZ), Berlin, Germany, ⁸Centro de Investigación Clínica de Morelia SC, Morelia, Mexico, ⁹Centre for Musculoskeletal Research, Division of Musculoskeletal and Dermatological Sciences, The University of Manchester, Manchester, United Kingdom, ¹⁰Eli Lilly and Company, Indianapolis, IN
Background/Purpose: Baricitinib (Bari), an oral selective inhibitor of Janus kinase (JAK)1 and JAK2, has been approved for the treatment of RA in the Europe and…
Abstract Number: 1671 • 2018 ACR/ARHP Annual Meeting
Laboratory Investigation Results Influence Physician’s Global Assessment of Disease Activity in Systemic Lupus Erythematosus
Cynthia Aranow¹, Anca Askanase², Molla Huq³, Shereen Oon⁴, Alicia Calderone⁴, Eric Morand⁵ and Mandana Nikpour⁶, ¹Feinstein Institute for Medical Research, Mahasset, NY, ²Columbia University, College of Physicians & Surgeons, New York, NY, ³The University of Melbourne at St Vincent's Hospital, Melbourne, Australia, ⁴The University of Melbourne at St. Vincent’s Hospital, Melbourne, Australia, ⁵Monash University, Melbourne, Australia, ⁶The University of Melbourne, Melbourne, Australia, Melbourne, Australia
Background/Purpose: The Physician Global Assessment (PGA) is a frequently-used outcome measure in Systemic Lupus Erythematosus (SLE). The PGA is intended to encapsulate the physician’s judgement…
Abstract Number: 1678 • 2018 ACR/ARHP Annual Meeting
How Consistently Do Publications Define SLE? a Systematic Review
Linjia Jia¹, Ecem Sevim², Medha Barbhaiya² and Michael Lockshin³, ¹Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, ²Rheumatology, Hospital for Special Surgery, New York, NY, ³Barbara Volcker Center, Hospital for Special Surgery, New York, NY
Background/Purpose: Systemic lupus erythematosus (SLE) is clinically heterogeneous. ACR and/or SLICC classification criteria provide homogeneous populations for research purposes, but studies differ in selection and…
Abstract Number: 1695 • 2018 ACR/ARHP Annual Meeting
Differences between Early and Adult-Onset Systemic Lupus Erythematosus in Cohort of Argentinian Patients
Rodrigo Aguila Maldonado¹, Dora Pereira², Gisela Pendon³, Alberto Spindler⁴, Cecilia N. Pisoni⁵, Julio Hofman⁶, María Victoria Collado⁷, Judith Sarano⁸, Cesar Graf⁹, Graciela N Gómez¹⁰, Paula Alba¹¹, Claudia Elizabeth Pena¹, Ana Carolina Costi¹², Adrian Salas¹³, Ana Curti¹⁴, Oscar Rillo¹⁵, Silvia Beatriz Papasidero¹⁶, Veronica Bellomio¹⁷, Susana Roverano¹⁸, Marcela Schmid¹⁹, Alberto Allievi²⁰, Sebastián Muñoz²⁰, Walter J. Spindler²¹, Andrea Gonzalez²², Ana María Beron²³, Rosana Quintana²⁴, Agustina Damico²⁵, Andrea Gómez²⁶, Sergio Tolosa²⁷, Enrique Soriano²⁸, Alicia Eimon²⁹, Marta Silvia Espósito⁶, Leila Romina Ferreyra Mufarregue³⁰, Juan Pablo Ruffino³⁰, Verónica Saurit³¹, Edson Hernán Chiganer³⁰, Fabian Risueño³², Flavia Caputo³³, Edson Velozo³⁴, Juan Soldano³⁵, Monica Diaz³⁶ and Mercedes Garcia¹, ¹Rheumatology, HIGA General San Martin La Plata, La Plata, Argentina, ²Rheumatology Section, Hospital Dr. Ricardo Gutiérrez, Argentina, Buenos Aires, Argentina, ³H Gutiérrez de La Plata, La Plata, Argentina, ⁴Centro Médico Privado de Reumatología, Centro Médico Privado de Reumatología, Argentina, ⁵Internal Medicine, CEMIC, Rheumatology and Immunology, CEMIC, Buenos Aires, Argentina, ⁶Consultorio Privado, Buenos Aires, Argentina, ⁷Rheumatology, Instituto de Investigaciones Medicas Alfredo Lanari, Buenos Aires, Argentina, ⁸Instituto Lanari, Buenos Aires, Argentina, ⁹Centro Médico Mitre, Paraná, Argentina, ¹⁰Diaz Colodrero 2537 8° A, Instituto de Investigaciones Medicas Alfredo Lanari, Capital Federal, Argentina, ¹¹Universidad Nacional de Cordoba, Rheumatology Unit Cordoba and Materno Neonatal Hospital, Córdoba, Argentina, ¹²Rheumatology Section, HIGA General San Martin La Plata, La Plata, Argentina, ¹³Rheumatology, HIGA General San Martin, La Plata, Argentina, ¹⁴Htal Lagomaggiori, Mendoza, Argentina, ¹⁵Hospital General de Agudos Dr Ignacio Pirovano, Argentina, Buenos Aires, Argentina, ¹⁶Rheumatology Section, Hospital General de Agudos Dr. Enrique Tornú, Argentina, Buenos Aires, Argentina, ¹⁷Hospital Padilla, San Miguel de Tucumán, Argentina, ¹⁸Hospital José Maria Cullen, Santa Fe, Argentina, ¹⁹Hospital Jose María Cullen, Santa Fe, Argentina, ²⁰SAR, Buenos Aires, Argentina, ²¹Centro Médico Privado de Reumatología, Tucuman, Argentina, ²²Hospital Eva Perón, San Martín, Argentina, ²³Hospital de Clínicas, Buenos Aires, Argentina, ²⁴Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario, Rosario, Argentina, ²⁵Hospital Británico, Buenos Aires, Argentina, ²⁶Hospital Británico de Buenos Aires, CABA, Argentina, ²⁷Hospital San Juan Bautista, San Fernando del Valle de Catamarca, Argentina, ²⁸Hospital Italiano, Buenos Aires, Argentina, ²⁹CEMIC, Buenos Aires, Argentina, ³⁰Hospital Durand, Buenos Aires, Argentina, ³¹Hospital Privado Centro Médico de Córdoba, Cordoba, Argentina, ³²Itemédica, Bahia Blanca, Argentina, ³³Hospital Posadas, Buenos Aires, Argentina, ³⁴Sanatorio Adventista del Plata, Entre Ríos, Ecuador, ³⁵Hospital Provincial, Rosario, Argentina, ³⁶SAR, Bariloche, Argentina
Background/Purpose: Approximately 20% of patients with Systemic Lupus Erythematosus (SLE) begin their illness in childhood or adolescence. These patients are described with a phenotype of…
Abstract Number: 2668 • 2018 ACR/ARHP Annual Meeting
Hydroxychloroquine and the Risk of Thrombotic Events in Systemic Lupus Erythematosus Patients : A Systematic Review and Meta-Analysis
Pratyaksha Sankhyan¹, Boonphiphop Boonpheng² and Christopher Cook², ¹Internal Medicine, East Tennessee State University, Johnson city, TN, ²Internal Medicine, East Tennessee State University, johnson city, TN
Hydroxychloroquine and Risk of Thrombosis in Patients with Systemic Lupus Erythematosus: A Systematic Review and Meta-analysisAuthors : Sankhyan P, Boonpheng B, Cook CT Background/Purpose: Over…
Abstract Number: 2677 • 2018 ACR/ARHP Annual Meeting
A Systematic Review Examining the Association between Organ Damage and Health-Related Quality of Life in Systemic Lupus Erythematosus
Edward R. Hammond¹, Dora H. Lin², Irene B. Murimi², Henk Nab³, Hong Kan², Oluwadamilola Onasanya², Jonothan Tierce², Xia Wang¹, Barnabas Desta¹ and G. Caleb Alexander², ¹AstraZeneca, Gaithersburg, MD, ²Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, ³AstraZeneca, Cambridge, United Kingdom
Background/Purpose: SLE-related organ damage is associated with increased morbidity. The comorbidity burden of SLE can involve various organ systems and may include pain, fatigue, difficulty…
Abstract Number: 2627 • 2017 ACR/ARHP Annual Meeting
Characterization of Emergency Department Visits in an Urban Underserved Lupus Cohort
Justin Levinson¹, Maushmi Savjani¹, Diane Zisa² and Ellen M. Ginzler³, ¹Internal Medicine, Division of Rheumatology, Department of Medicine, SUNY Downstate Medical Center, Brooklyn, NY, ²Division of Rheumatology, Department of Medicine, SUNY Downstate Medical Center, Brooklyn, NY, ³Rheumatology, Division of Rheumatology, Department of Medicine, SUNY Downstate Medical Center, Brooklyn, NY
Background/Purpose: SLE patients frequently utilize the Emergency Department (ED), impacting the cost of care and quality of life. We performed a retrospective analysis of ED…
Abstract Number: 2629 • 2017 ACR/ARHP Annual Meeting
Systemic Lupus Erythematosus Patients Not Complaining Raynaud’s Phenomenon Display Lower Skin Blood Perfusion Than Healthy Subjects
Barbara Ruaro¹, Alberto Sulli¹, Sabrina Paolino², Carmen Pizzorni³, Veronica Tomatis¹, Massimo Patanè¹ and Maurizio Cutolo¹, ¹Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, Genoa, Italy, Genoa, Italy, ²University of Genova, IRCCS San Martino, Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, Genoa, Italy, Genova, Italy, ³Research Laboratory and Academic Unit of Clinical Rheumatology, Department of Internal Medicine, University of Genova, Genova, Italy, Genova, Italy
Background/Purpose: A clinical feature of patients with primary Raynaud's phenomenon (PRP) is the presence of low skin blood perfusion (BP) at the level of hands…

All abstracts accepted to PRYSM are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 6:00 PM CT on March 18. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].